We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Fate Therapeutics Treats First Patient in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
News

Fate Therapeutics Treats First Patient in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

Fate Therapeutics Treats First Patient in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
News

Fate Therapeutics Treats First Patient in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Fate Therapeutics Treats First Patient in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Fate Therapeutics, Inc. announced has that the first patient has been treated in a Phase 1b clinical trial of FT1050, a small molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem cell (HSC) number and function through its activation of key pathways that guide cell fate.

The study, which is being conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts, will determine the safety and tolerability of introducing FT1050 during the standard course of dual umbilical cord blood transplant in adult patients with hematologic malignancies, such as leukemia and lymphoma, who have undergone nonmyeloablative conditioning therapy. Fate Therapeutics is developing FT1050 to improve the overall efficiency of HSC treatment by enhancing HSC proliferation and homing to the bone marrow.

"The mission of Fate Therapeutics is to develop small molecules and biologics that modulate adult stem cells within the body for regenerative medicine," said Paul Grayson, president and CEO of Fate Therapeutics. "As our first SCM clinical candidate, FT1050 represents the initial step in our approach - using a small molecule to treat cells ex vivo but creating an in vivo regenerative effect. With FT1050, we are trying to affect stem cell biology in the body, improving the reconstitution of a patient's blood and immune system."

"For patients who need hematopoietic stem cell support, time is of the essence," said Corey Cutler M.D., M.P.H., F.R.C.P.C., assistant professor of medicine, Dana-Farber and Harvard Medical School, and leader of the clinical study.

"However, many patients do not have a suitably matched donor, either from a sibling or from an unrelated volunteer in the worldwide registries. Because umbilical cord blood units are readily available from cord blood banks, and the matching criteria for cord blood are less stringent than with adult donors, the ability to increase cord blood use by enhancing its efficiency has the potential to help thousands of patients waiting for a match."
Advertisement